Abciximab therapy is associated with increased platelet activation and decreased heparin dosage in patients with acute myocardial infarction

Summary

The inhibition of the glycoprotein (GP) IIb/IIIa receptor for reducing periprocedural ischemic events in patients undergoing coronary intervention is known to influence platelet reactivity. Suboptimal doses of GP IIb/IIIa antagonists have been suggested to be prothrombotic and proinflammatory. This study was performed to observe platelet activation markers, whole blood aggregation and the dosage of unfractionated heparin (UFH) in the presence or absence of the GP IIb/IIIa inhibitor abciximab. Patients with acute myocardial infarction undergoing percutaneous coronary intervention were treated with (n=15) or without (n=15) abciximab. Platelet activation markers were flow cytometrically measured before and after PCI. Whole blood platelet aggregation was tested by a platelet function assay. The patients with abciximab showed a significant increase in platelet activation markers (P-selectin: 7.12 ± 0.36 AU vs 11.05 ± 0.79 AU) and a lower requirement of UFH to prolong aPTT > 60 sec during the infusion. 12 hours after infusion P-selectin level decreased (7.20 ± 0.58 AU), whereas whole blood aggregation was increasing again. After stopping abciximab, requirement of UFH to prolong aPTT increased in the treated group to a greater extent to a level similar to the untreated group even when most of the platelets were still inhibited. The increased platelet activation found at the end of abciximab treatment points to a procoaguable condition that should be carefully monitored and treated by adapting anticoagulation and antiplatelet drugs.

Keywords

Abciximab - heparin - platelet activation

• References

• 1 Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994; 330: 956-61.
• 2 Randomised placebo-controlled and balloon-angioplasty- controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998; 352: 87-92.
• 3 Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997; 336: 1689-96.
• 4 Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. The GUSTO IVACS Investigators. Lancet 2001; 357: 1905-14.
• 5 Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non- Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 1998; 338: 1488-97.
• 6 Peter K, Schwarz M, Ylanne J. et al. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors. Blood 1998; 92: 3240-9.
• 7 Schneider DJ, Taatjes DJ, Sobel BE. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa. Cardiovasc Res 2000; 45: 437-46.
• 8 Rossi F, Rossi E, Pareti FI. et al. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion. Haematologica 2001; 86: 192-8.
• 9 Quinn MJ, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword?. Circulation 2002; 106: 379-85.
• 10 Angiolillo DJ, Sabate M, Fernandez-Ortiz A. et al. Aute stent thrombosis after early withdrawal of platelet glycoprotein IIb/IIIa antagonists: potential rebound prothrombotic effect?. Catheter Cardiovasc Interv 2003; 58: 481-4.
• 11 Aguirre FV, Topol EJ, Ferguson JJ. et al. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators. Circulation 1995; 91: 2882-90.
• 12 Weikert U, Kuhl U, Schultheiss HP. Increased platelet activation in patients with cardiomyopathy: Myocardial inflammation and platelet reactivity. Platelets 2002; 13: 487-91.
• 13 Jaster M, Fuster V, Rosenthal P. et al. Catheter based intracoronary brachytherapy leads to increased platelet activation. Heart 2004; 90: 160-4.
• 14 Jaster M, Schwimmbeck P, Spencker S. et al. Randomized comparison of platelet-leukocyte aggregates and platelet activation in blood: heparin-coated coiled wire stent implantation versus balloon angioplasty in acute myocardial infarction. Thromb Res 2003; 112: 285-9.
• 15 Piorkowski M, Weikert U, Schwimmbeck PL. et al. ADP induced platelet degranulation in healthy individuals is reduced by clopidogrel after pretreatment with atorvastatin. Thromb Haemost 2004; 92: 614-20.
• 16 Smith JW, Steinhubl SR, Lincoff M. Rapidplateletfunction assay. An automated and quantitative cartridge- based method. Circulation 1999; 99: 620-5.
• 17 Osende JI, Fuster V, Lev EI. Testingplateletactivation with a shear-dependent platelet function test versus aggregation-based tests. Relevance for monitoring long-term glycoprotein IIb/IIIa inhibition. Circulation 2001; 103: 1488-91.
• 18 Steinhubl SR, Talley JD, Braden GA. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention. Results of the GOLD (AU-assessing Ultegra) multicenter study. Circulation 2001; 103: 2572-8.
• 19 Nannizzi-Alaimo L, Alves VL, Phillips DR. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation 2003; 107: 1123-8.
• 20 Cox D, Smith R, Quinn M. et al. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. J Am Coll Cardiol 2000; 36: 1514-9.
• 21 Holmes MB, Sobel BE, Cannon CP, Schneider DJ. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orbofiban in Patients with Unstable coronary syndromes. Thrombolysis In Myocardial Infarction. Am J Cardiol 2000; 85: 491-3 A10.
• 22 Collet JP, Montalescot G, Lesty C. et al. Effects of Abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention. Circulation 2001; 103: 2328-31.
• 23 Goto S, Tamura N, Ishida H. Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions. J Am Coll Cardiol 2004; 44: 316-23.
• 24 Ammar T, Scudder LE, Coller BS. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation 1997; 95: 614-7.
• 25 Moliterno DJ, Califf RM, Aguirre FV. et al. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol 1995; 75: 559-62.
• 26 Ambrose JA, Hawkey M, Badimon JJ. et al. In vivo demonstration of an antithrombin effect of abciximab. Am J Cardiol 2000; 86: 150-2.
• 27 Butenas S, Cawthern KM, van’t Veer C, et al. Lock JB, Mann KG. Antiplatelet agents in tissue factor-induced blood coagulation. Blood 2001; 97: 2314-22.
• 28 Reverter JC, Beguin S, Kessels H. et al. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and ‘‘clinical restenosis”. J Clin Invest 1996; 98: 863-74.